BioPhotas Receives FDA Clearance for the Celluma

March 4, 2016

BioPhotas has landed FDA clearance for its patented biophotonic medical device, the Celluma, indicated for treating facial wrinkles.

Previously, the low-level light therapy device was cleared for the following indications: the treatment of acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation, the company says.

In a clinical study, participants saw a reduction in facial wrinkles 12 weeks after a four-week treatment period was completed.

The Celluma uses three wavelengths of light simultaneously to treat multiple skin, muscle and joint conditions. — Anisa Jibrell